[Federal Register: October 18, 2006 (Volume 71, Number 201)]
[Notices]
[Page 61525-61528]
[DOCID:fr18oc06-108]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-54590; File No. SR-NYSEArca-2006-73]

Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Filing
of Proposed Rule Change To Create a Penny Pilot Program for Options
Trading

October 12, 2006.
    Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934

(``Act'') \1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on October 10, 2006, NYSE Arca, Inc. (``NYSE Arca'' or ``Exchange'')
filed with the Securities and Exchange Commission (``Commission'') the
proposed rule change as described in Items I, II, and III below, which
Items have been substantially prepared by the Exchange. The Commission
is publishing this notice to solicit comments on the proposed rule
change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    NYSE Arca proposes to: (i) Clarify the language in NYSE Arca Rule
6.72; (ii) add a reference to a six month penny pilot in options
classes in certain issues approved by the Commission (``Pilot
Program''); and (iii) provide for an approved quote mitigation
exception to NYSE Arca Rule 6.86. The text of the proposed rule is
available on NYSE Arca's Web site at http://www.nysearca.com, at the

Exchange's Office of the Secretary, and at the Commission's Public
Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
Sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    NYSE Arca Rule 6.72(a) sets forth the trading increments for option
contracts quoted on the Exchange. Currently, the minimum price
variation (``MPV'') for option series that are quoted under $3.00 per
contract is $0.05 and the MPV for option series that are quoted at
$3.00 per contract or greater is $0.10. The Exchange is proposing to:
(i) Clarify the language in NYSE Arca Rule 6.72; and (ii) add a
reference to a six month penny pilot in options traded on a limited
number of classes approved by the Commission.
    The Exchange proposes to clarify existing language in NYSE Arca
Rule 6.72 to continue a $0.05 MPV for quoting in all options series
trading at less than $3.00, and $0.10 MVP for quoting in all options
series trading at $3.00 or more, except those included in the Pilot
Program described below.
Pilot Program
    The Exchange proposes to provide for a penny MPV in options
contracts in certain classes approved by the Commission. The Exchange
believes that migrating to penny pricing in these classes will create
tighter markets and thus reduce the overall cost of trading in options
for investors. Despite the overall benefits provided to investors in
migrating to penny pricing, the Exchange believes it is critical to
introduce pennies in a measured approach that will not exacerbate the
existing quote capacity limitations that currently exist.
    The Exchange proposes that options classes in the following issues
be approved for inclusion in a Penny Pilot:

QQQQ: Nasdaq-100 Index Tracking Stock
IWM: iShares Russell 2000 Index Fund
SMH: Semiconductor Holdrs Trust
GE: General Electric Company
AMD: Advanced Micro Devices, Inc.
MSFT: Microsoft Corporation
INTC: Intel Corporation
CAT: Caterpillar Inc.
WFMI: Whole Foods Market, Inc.
TXN: Texas Instruments Incorporated
GLG: Glamis Gold Ltd.
FLEX: Flextronics International Ltd.
SUNW: Sun Microsystems, Inc.

    Under the proposed Pilot Program, the Exchange will allow trading
and quoting in increments of $0.01 for all options on the QQQQ, and
will allow trading and quoting in pennies for series in all other Pilot
classes approved by the Commission that are trading below $3.00. Pilot
classes with series trading at or above $3.00 would have a $0.05
quoting MPV. The Exchange anticipates the Commission will approve
options classes in issues with a contrasting range of trading activity
so that the Exchange and the industry may better understand the effects
of the Pilot Program. The Exchange intends to include any option
approved as eligible for the Pilot Program for penny trading and
quoting. The Exchange believes the Commission should approve a variety
of option classes for inclusion in a pilot broad enough to encompass
differing quote and trade activity levels.
    The Exchange will continue to abide by the existing Options Linkage
Plan (``Linkage'') as described in NYSE Arca Rules 6.93 and 6.94 with
respect to linkage operation and order protection. If the Exchange
receives an order through Linkage in a Pilot Program series from
another exchange not quoting and trading in pennies, the Exchange will
fill the incoming order at a penny incremented price, as long as the
execution price is equal to or better than the reference price of the
Linkage order. In the event of a trade through by another Linkage
Participant Market of a customer order in a Pilot Program issue that
has been denominated and disseminated to the Options Price Reporting
Authority (``OPRA'') in a penny increment, the Exchange will assign a
reference price on an outbound Satisfaction order in the penny
incremented price of the customer order. The Exchange believes that a
Linkage Participant market that receives a Satisfaction order in a
penny increment should be permitted to fill the Satisfaction order at
its reference price; regardless of the actual MPV permitted at the
recipient exchange. If a Participating Market is not capable of
processing and reporting a transaction in a penny increment, the
Exchange believes that it is consistent with the intent of the Linkage
plan that the receiving market should fill the Satisfaction order at
the next best MPV allowed in that series on the receiving exchange. The
Exchange would accept an execution report at that price, and fill the
customer order that had been traded through at the price received on
the Satisfaction order.
    As is widely acknowledged, the options industry is facing
significant capacity issues related to excessive quoting rates. Peak
quote rates \3\ through April 2006 as reported by OPRA, the processor
that disseminates quote and trade data for the options industry, have
increased to 7 times the 2003 peak quote rates. In the last year, peak
rates have more than doubled. In order to limit the capacity impact of
migrating to penny trading, the Exchange proposes to limit the pilot to
options on QQQQ and other issues approved by the Commission. This will
allow the Exchange to carefully study the impact and assess the outcome
of penny trading on data traffic. Further, in conjunction with the
pilot, the Exchange proposes a strategy to mitigate the volume of data
being processed and disseminated by OPRA.
---------------------------------------------------------------------------

    \3\ Peak quote rates are measured in messages per second over a
1 minute period.
---------------------------------------------------------------------------

    Sixty days prior to the expiration of the Pilot Program, the
Exchange agrees to submit a report to the Commission that includes: (i)
Data and written

analysis on the number of quotations generated for options selected for
the Pilot Program; (ii) an assessment of the quotation spreads for the
options selected for the Pilot Program; (iii) an assessment of the
impact of the Pilot Program on the capacity of the NYSE Arca's
automated systems; (iv) any capacity problems or other problems that
arose related to the operation of the Pilot Program and how the NYSE
Arca addressed them; and (v) an assessment of trade through complaints
that were sent by the NYSE Arca during the operation of the Pilot
Program and how they were addressed. The report will study data
produced in the first three months of the Pilot Program.
Quote Mitigation Strategy
    NYSE Arca Rule 6.86 describes the obligations of the Exchange to
collect, process and make available to quotation vendors the best bid
and best offer for each option series that is a reported security. The
Exchange proposes an exception to making quotes available to quotation
vendors as part of an approved quote mitigation plan. The quote
mitigation strategy proposed by the Exchange is intended to reduce the
number of quotations generated by NYSE Arca for all option issues
traded at NYSE Arca, not just issues included in the Pilot Program.
NYSE Arca plans to reduce the number of quote messages it sends to OPRA
by only submitting quote messages for ``active'' options series. Active
options series are defined as the following: (i) The series has traded
on any options exchange in the previous 14 calendar days; or, (ii) the
series is solely listed on NYSE Arca; or (iii) the series has been
trading ten days or less; or, (iv) the Exchange has an order in the
series. For any options series that falls into one of the
aforementioned categories, NYSE Arca will submit quotes to OPRA as it
currently does. For any options series that falls outside of the above
categories, NYSE Arca will still accept quotes from OTP Holders in
these series; however, such quotes will not be disseminated to OPRA.
    In addition, there are certain instances when a series would become
active intraday. Such instances include: (i) The series trades at any
options exchange; (ii) NYSE Arca receives an order in the series; or
(iii) NYSE Arca receives a request for quote from a customer in that
series. When one of the above circumstances exists, NYSE Arca would
immediately begin disseminating quotes to OPRA in that particular
series and would continue doing so until that series fell outside of
the active series definition. If the series does not trade, and there
are no orders in the series the next day, the series would no longer be
considered active. Further, because NYSE Arca will continue to collect
quotes from OTP Holders in inactive series, upon receiving an order in
an inactive series, the Exchange will either execute that order against
any marketable quotes in the trading system, or will link that order to
the away market displaying the NBBO in that series. Accordingly, OTP
Holders' orders will not be disadvantaged and will still have an
opportunity to execute at the best price in such inactive series.
    Based upon studies conducted by the Exchange, it appears less than
25% of the industry's available options series trade each day. In
addition, on NYSE Arca on any given day, 75% of the trading volume
occurs in options on 200 underlying securities out of a possible 2,000
underlying securities that have listed options contracts listed on NYSE
Arca. Accordingly, the Exchange felt it was prudent to analyze the
quoting behavior in such inactive series. Based upon the analysis, the
Exchange determined that it was possible to reduce quote traffic by 20-
30% by limiting quote dissemination to solely active series as
described above. As a result, the Exchange believes its proposed data
mitigation strategy will have a significant effect on reducing quote
traffic and addressing the current capacity problems facing the
industry.
2. Statutory Basis
    The Exchange believes that its proposed rule change is consistent
with section 6(b) of the Act,\4\ in general, and furthers the
objectives of section 6(b)(5) of the Act,\5\ in particular, in that it
is designed to prevent fraudulent and manipulative acts and practices,
to promote just and equitable principals of trade, to foster
cooperation and coordination with persons engaged in facilitating
transactions in securities, and to remove impediments to and perfect
the mechanism of a free and open market and a national market system.
---------------------------------------------------------------------------

    \4\ 15 U.S.C. 78f(b).
    \5\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition that is not necessary or appropriate
in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    Written comments on the proposed rule change were neither solicited
nor received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Within 35 days of the date of publication of this notice in the
Federal Register or within such longer period (i) as the Commission may
designate up to 90 days of such date if it finds such longer period to
be appropriate and publishes its reasons for so finding or (ii) as to
which the Exchange consents, the Commission will:
    (A) By order approve such proposed rule change; or
    (B) Institute proceedings to determine whether the proposed rule
change should be approved.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views and
arguments concerning the foregoing, including whether the proposed rule
is consistent with the Act. Comments may be submitted by any of the
following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml.
); or     Send an e-mail to<EMAIL_ADDRESS>Please include

File Number SR-NYSEArca-2006-73 on the subject line.

Paper Comments

     Send paper comments in triplicate to Nancy M. Morris,
Secretary, Securities and Exchange Commission, Station Place, 100 F
Street, NE., Washington, DC 20549-1090.
    All submissions should refer to File Number SR-NYSEArca-2006-73.
This file number should be included on the subject line if e-mail is
used. To help the Commission process and review your comments more
efficiently, please use only one method. The Commission will post all
comments on the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml
). Copies of the submission, all subsequent amendments,

all written statements with respect to the proposed rule change that
are filed with the Commission, and all written communications relating
to the proposed rule change between the Commission and any person,
other than those that may be withheld from the

public in accordance with the provisions of 5 U.S.C. 552, will be
available for inspection and copying in the Commission's Public
Reference Section, Station Place, 100 F Street, NE., Washington, DC
20549-1090. Copies of such filing also will be available for inspection
and copying at the principal office of NYSE Arca. All comments received
will be posted without change; the Commission does not edit personal
identifying information from submissions. You should submit only
information that you wish to make available publicly. All submissions
should refer to File Number SR-NYSEArca-2006-73 and should be submitted
on or before November 8, 2006.

    For the Commission, by the Division of Market Regulation,
pursuant to delegated authority.\6\
---------------------------------------------------------------------------

    \6\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

J. Lynn Taylor,
Assistant Secretary.
[FR Doc. E6-17317 Filed 10-17-06; 8:45 am]

BILLING CODE 8011-01-P


[Federal Register Volume 85, Number 101 (Tuesday, May 26, 2020)]
[Notices]
[Pages 31541-31542]
[FR Doc No: 2020-11166]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Internal Agency Docket No. FEMA-4498-DR; Docket ID FEMA-2020-0001]

Colorado; Major Disaster and Related Determinations

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice of the Presidential declaration of a major
disaster for the State of Colorado (FEMA-4498-DR), dated March 28,
2020, and related determinations.

DATES: The declaration was issued March 28, 2020.

FOR FURTHER INFORMATION CONTACT: Dean Webster, Office of Response and
Recovery, Federal Emergency Management Agency, 500 C Street SW,
Washington, DC 20472,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: Notice is hereby given that, in a letter
dated March 28, 2020, the President issued a major disaster declaration
under the authority of the Robert T. Stafford Disaster Relief and
Emergency Assistance Act, 42 U.S.C. 5121 et seq. (the ``Stafford
Act''), as follows:

    I have determined that the emergency conditions in the State of
Colorado resulting from the Coronavirus Disease 2019 (COVID-19)
pandemic beginning on January 20, 2020, and continuing, are of
sufficient severity and magnitude to warrant a major disaster
declaration under the Robert T. Stafford Disaster Relief and
Emergency Assistance Act, 42 U.S.C. 5121 et seq. (the ``Stafford
Act''). Therefore, I declare that such a major disaster exists in
the State of Colorado.
    In order to provide Federal assistance, you are hereby
authorized to allocate from funds available for these purposes such
amounts as you find necessary for Federal disaster assistance and
administrative expenses.
    You are authorized to provide assistance for emergency
protective measures (Category B), including direct Federal
assistance, under the Public Assistance program throughout the
State. Consistent with the requirement that Federal assistance be
supplemental, any Federal funds provided under the Stafford Act for
Public Assistance will be limited to 75 percent of the total
eligible costs.
    Further, you are authorized to make changes to this declaration
for the approved assistance to the extent allowable under the
Stafford Act.

    The Federal Emergency Management Agency (FEMA) hereby gives notice
that pursuant to the authority vested in the Administrator, under
Executive Order 12148, as amended, Lee K. dePalo, of FEMA is appointed
to act as the Federal Coordinating Officer for this major disaster.
    The following areas of the State of Colorado have been designated
as adversely affected by this major disaster:

    Emergency protective measures (Category B) not authorized under
other Federal statutes, including direct Federal assistance, under
the Public Assistance program at 75 percent federal funding for all
areas in the State of Colorado.

The following Catalog of Federal Domestic Assistance Numbers (CFDA)
are to be used for reporting and drawing funds: 97.030, Community
Disaster Loans; 97.031, Cora Brown Fund; 97.032, Crisis Counseling;
97.033, Disaster Legal Services; 97.034, Disaster Unemployment
Assistance (DUA); 97.046, Fire Management Assistance Grant; 97.048,
Disaster Housing Assistance to Individuals and Households In
Presidentially Declared Disaster Areas; 97.049, Presidentially
Declared Disaster Assistance--Disaster Housing Operations for
Individuals and Households; 97.050, Presidentially Declared Disaster
Assistance to Individuals and Households--Other Needs; 97.036,
Disaster Grants--Public Assistance

(Presidentially Declared Disasters); 97.039, Hazard Mitigation
Grant.

Pete Gaynor,
Administrator, Federal Emergency Management Agency.
[FR Doc. 2020-11166 Filed 5-22-20; 8:45 am]
BILLING CODE 9111-23-P


[Federal Register: July 24, 2006 (Volume 71, Number 141)]
[Notices]
[Page 41795-41796]
[DOCID:fr24jy06-70]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project Nos. 2698-033, 2686-032, 2602-007, and 2601-007 North
Carolina]

Duke Power Company LLC; Notice of Availability of Final
Environmental Assessment

July 14, 2006.
    In accordance with the National Environmental Policy Act of 1969,
as amended, and Federal Energy Regulatory Commission (Commission)
regulations (18 CFR part 380), Commission staff reviewed the
applications for new major licenses for the East and West Fork
projects, a subsequent license for the Bryson Project, and the
application for license surrender for the Dillsboro Project. We
prepared a combined environmental assessment (EA) on the proposed

actions. The East and West Fork and Dillsboro projects are located on
the Tuckasegee River in Jackson County, North Carolina. The Bryson
Project is located on the Oconaluftee River (a tributary to the
Tuckasegee River) in Swain County, North Carolina.
    In this final EA, Commission staff analyze the probable
environmental effects of implementing the projects and conclude that
approval of the projects, with appropriate staff-recommended
environmental measures, would not constitute a major federal action
significantly affecting the quality of the human environment.
    Copies of the final EA are available for review in Public Reference
Room 2-A of the Commission's offices at 888 First Street, NE.,
Washington, DC. The EA also may be viewed on the Commission's Internet
Web site (http:///www.ferc.gov) using the ``eLibrary'' link. Additional

information about the project is available from the Commission's Office
of External Affairs at<PHONE_NUMBER>, or on the Commission's Web site
using the eLibrary link. For assistance with eLibrary, contact
<EMAIL_ADDRESS>or call toll-free at<PHONE_NUMBER>; for TTY

call<PHONE_NUMBER>.
    For further information, please contact Carolyn Holsopple at (202)
502-6407 or at<EMAIL_ADDRESS>
Magalie R. Salas,
Secretary.
[FR Doc. E6-11663 Filed 7-21-06; 8:45 am]

BILLING CODE 6717-01-P


[Federal Register Volume 87, Number 242 (Monday, December 19, 2022)]
[Notices]
[Pages 77617-77619]
[FR Doc No: 2022-27428]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-2810]

Vaccines and Related Biological Products Advisory Committee;
Notice of Meeting; Establishment of a Public Docket; Request for
Comments

AGENCY: Food and Drug Administration, Department of Health and Human
Services (HHS).

ACTION: Notice; establishment of a public docket; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Vaccines and Related
Biological Products Advisory Committee (VRBPAC). The general function
of the committee is to provide advice and recommendations to FDA on
regulatory issues. On January 26, 2023, the committee will meet in open
session to discuss the future vaccination regimens addressing COVID-19.
The meeting will be open to the public. FDA is establishing a docket
for public comment on this document.

DATES: The meeting will be held virtually on January 26, 2023, from
8:30 a.m. to 5:30 p.m. Eastern Time.

ADDRESSES: Please note that due to the impact of this COVID-19
pandemic, all meeting participants will be joining this advisory
committee meeting via an online teleconferencing platform. Answers to
commonly asked questions about FDA advisory committee meetings,
including information regarding special accommodations due to a
disability, may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm. The online web conference
meeting will be available at the following link on the day of the
meeting: https://youtu.be/ZjULNuSYfd0.
    FDA is establishing a docket for public comment on this meeting.
The docket number is FDA-2022-N-2810. Please note that late, untimely
filed comments will not be considered. The docket will close on January
25, 2023. Either electronic or written comments on this public meeting
must be submitted by January 25, 2023. The https://www.regulations.gov
electronic filing system will accept comments until 11:59 p.m. Eastern
Time at the end of January 25, 2023. Comments received by mail/hand
delivery/courier (for written/paper submissions) will be considered
timely if they are received on or before that date.
    Comments received on or before January 18, 2023, will be provided
to the committee. Comments received after January 18, 2023, and by
January 25, 2023, will be taken into consideration by FDA. In the event
that the meeting is canceled, FDA will continue to evaluate any
relevant applications or information, and consider any comments
submitted to the docket, as appropriate.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your

comment does not include any confidential information that you or a
third party may not wish to be posted, such as medical information,
your or anyone else's Social Security number, or confidential business
information, such as a manufacturing process. Please note that if you
include your name, contact information, or other information that
identifies you in the body of your comments, that information will be
posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2022-N-2810 for ``Vaccines and Related Biological Products Advisory
Committee (VRBPAC); Notice of Meeting; Establishment of a Public
Docket; Request for Comments.'' Received comments, those filed in a
timely manner (see ADDRESSES), will be placed in the docket and, except
for those submitted as ``Confidential Submissions,'' publicly viewable
at https://www.regulations.gov or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday through Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' FDA will review
this copy, including the claimed confidential information, in its
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify the information as ``confidential.'' Any
information marked as ``confidential'' will not be disclosed except in
accordance with 21 CFR 10.20 and other applicable disclosure law. For
more information about FDA's posting of comments to public dockets, see
80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Sussan Paydar or Prabhakara Atreya,
Center for Biologics Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD
20993-0002,<PHONE_NUMBER>, [email protected]; or FDA Advisory
Committee Information Line, 1-800-741-8138<PHONE_NUMBER> in the
Washington, DC area). A notice in the Federal Register about last
minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check the FDA's website at
https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to
the appropriate advisory committee meeting link, or call the advisory
committee information line to learn about possible modifications before
coming to the meeting.

SUPPLEMENTARY INFORMATION:
    Agenda: The meeting presentations will be heard, viewed, captioned,
and recorded through an online teleconferencing platform. On January
26, 2023, the committee will meet in open session to discuss the future
vaccination regimens addressing COVID-19. This discussion will include
consideration of the composition and schedule of the primary series and
booster vaccinations.
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its website prior to the meeting, the
background material will be made publicly available at the time of the
advisory committee meeting, and the background material will be posted
on FDA's website after the meeting. Background material is available at
https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll
down to the appropriate advisory committee meeting link. The meeting
will include slide presentations with audio components to allow the
presentation of materials in a manner that most closely resembles an
in-person advisory committee meeting.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
All electronic and written submissions submitted to the Dockets (see
ADDRESSES) on or before January 18, 2023, will be provided to the
committee. Comments received after January 18, 2023, and by January 25,
2023, will be taken into consideration by FDA. Oral presentations from
the public will be scheduled between approximately 1:30 p.m. and 2:30
p.m. Eastern Time. Those individuals interested in making formal oral
presentations should notify the contact person and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, along with their names, email addresses, and direct contact
phone numbers of proposed participants, on or before 12 p.m. Eastern
Time on January 18, 2023. Time allotted for each presentation may be
limited. If the number of registrants requesting to speak is greater
than can be reasonably accommodated during the scheduled open public
hearing session, FDA may conduct a lottery to determine the speakers
for the scheduled open public hearing session. The contact person will
notify interested persons regarding their request to speak by 6 p.m.
Eastern Time January 20, 2023.
    For press inquiries, please contact the Office of Media Affairs at
[email protected] or<PHONE_NUMBER>.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Sussan Paydar or Prabhakara Atreya (see FOR FURTHER INFORMATION
CONTACT) at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our website at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on

public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: December 13, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-27428 Filed 12-16-22; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register: March 22, 2010 (Volume 75, Number 54)]
[Notices]
[Page 13612-13613]
[DOCID:fr22mr10-113]

=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

Proposed Collection; Comment Request

Upon Written Request, Copies Available From: Securities and Exchange
Commission, Office of Investor Education and Advocacy, Washington, DC
20549-0213.

Extension:
    Notice of Exempt Preliminary Roll-Up Communication, OMB Control
No. 3235-0452, SEC File No. 270-396

    Notice is hereby given that pursuant to the Paperwork Reduction Act
of 1995 (44 U.S.C. 3501 et seq.) the Securities and Exchange Commission
(``Commission'') is soliciting comments on the collection of
information summarized below. The Commission plans to submit this
existing collection of information to the Office of Management and
Budget for extension approval.
    A Notice of Exempt Preliminary Roll-Up Communication (``Notice'')
(17 CFR 240.14a-104) provides information regarding ownership interest
and any potential conflicts of interest to be included in statements
submitted by or on behalf of a person pursuant to Exchange Act Rule (17
CFR 240.14a-2(b)(4)) and Exchange Act Rule (17 CFR

240.14a-6(n)). The Notice takes approximately 0.25 hours per response
and is filed by 4 respondents for a total of one annual burden hour.
    Written comments are invited on: (a) Whether this proposed
collection of information is necessary for the proper performance of
the functions of the agency, including whether the information will
have practical utility; (b) the accuracy of the agency's estimate of
the burden imposed by the collection of information; (c) ways to
enhance the quality, utility, and clarity of the information collected;
and (d) ways to minimize the burden of the collection of information on
respondents, including through the use of automated collection
techniques or other forms of information technology. Consideration will
be given to comments and suggestions submitted in writing within 60
days of this publication.
    Please direct your written comments to Charles Boucher, Director/
CIO, Securities and Exchange Commission, C/O Shirley Martinson 6432,
General Green Way, Alexandria, Virginia 22312; or send an e-mail to:
<EMAIL_ADDRESS>
    Dated: March 16, 2010.
Florence E. Harmon,
Deputy Secretary.
[FR Doc. 2010-6152 Filed 3-19-10; 8:45 am]
BILLING CODE 8011-01-P